December 1, 2022Journal of Clinical OncologyOpen Access

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

View Full Paper

Ask AI

Bookmark

Abstract

In patients from Asia with previously treated advanced HCC, pembrolizumab significantly prolonged overall survival and PFS, and ORR was greater versus placebo.

Discussion

Member takes

Cite This Study

Qin et al. (2022) studied this question.

synapsesocial.com/papers/69d76dbdf44a16d01ef30f58 https://doi.org/10.1200/jco.22.00620

View Full Paper

Ask AI

Bookmark

Abstract

In patients from Asia with previously treated advanced HCC, pembrolizumab significantly prolonged overall survival and PFS, and ORR was greater versus placebo.